Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) read with Para A of Part A of Schedule III of the SEBI Listing Regulations, Biocon has informed that Biocon Biologics, a subsidiary of Biocon has approved the transfer of businesses in relation to its branded formulationsin India, comprising of Metabolics, Oncology And Critical Care Diagnostic (BFI Business) to Eris Lifesciences on a ‘slump sale’ basis. In this regard, it has enclosed the Press Release titled ‘Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India’. Further, the details as required under Regulation 30 of SEBI Listing Regulations read with SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as ‘Annexure - I’.
The above information is a part of company’s filings submitted to BSE.
